Low prevalence of neurocognitive impairment in early diagnosed and managed HIV-infected persons

Nancy F. Crum-Cianflone, David J. Moore, Scott Letendre, Mollie Poehlman Roediger, Lynn Eberly, Amy Weintrob, Anuradha Ganesan, Erica Johnson, Raechel Del Rosario, Brian K. Agan, Braden R. Hale

Research output: Contribution to journalArticle

Abstract

Objective: To describe the prevalence of neurocognitive impairment (NCI) among early diagnosed and managed HIV-infected persons (HIV+) compared to HIV-negative controls. Methods: We performed a cross-sectional study among 200 HIV+ and 50 matched HIV-uninfected (HIV-) military beneficiaries. HIV+ patients were categorized as earlier (200 cells/mm3) or later stage patients (n = 100 in each group); both groups were diagnosed early and had access to care. NCI was diagnosed using a comprehensive battery of standardized neuropsychological tests. Results: HIV+ patients had a median age of 36 years, 91% were seroconverters (median window of 1.2 years), had a median duration of HIV of 5 years, had a CD4 nadir of 319, had current CD4 of 546 cells/mm3, and 64% were on highly active antiretroviral therapy (initiated 1.3 years after diagnosis at a median CD4 of 333 cells/mm3). NCI was diagnosed among 38 (19%, 95% confidence interval 14%-25%) HIV+ patients, with a similar prevalence of NCI among earlier and later stage patients (18% vs 20%, p = 0.72). The prevalence of NCI among HIV+ patients was similar to HIV-patients. Conclusions: HIV+ patients diagnosed and managed early during the course of HIV infection had a low prevalence of NCI, comparable to matched HIV-uninfected persons. Early recognition and management of HIV infection may be important in limiting neurocognitive impairment.

Original languageEnglish (US)
Pages (from-to)371-379
Number of pages9
JournalNeurology
Volume80
Issue number4
DOIs
StatePublished - Jan 22 2013
Externally publishedYes

Fingerprint

HIV
Impairment
Person
AIDS/HIV
HIV Infections
Neuropsychological Tests
Highly Active Antiretroviral Therapy
Cross-Sectional Studies
Confidence Intervals

ASJC Scopus subject areas

  • Clinical Neurology
  • Arts and Humanities (miscellaneous)

Cite this

Crum-Cianflone, N. F., Moore, D. J., Letendre, S., Roediger, M. P., Eberly, L., Weintrob, A., ... Hale, B. R. (2013). Low prevalence of neurocognitive impairment in early diagnosed and managed HIV-infected persons. Neurology, 80(4), 371-379. https://doi.org/10.1212/WNL.0b013e31827f0776

Low prevalence of neurocognitive impairment in early diagnosed and managed HIV-infected persons. / Crum-Cianflone, Nancy F.; Moore, David J.; Letendre, Scott; Roediger, Mollie Poehlman; Eberly, Lynn; Weintrob, Amy; Ganesan, Anuradha; Johnson, Erica; Rosario, Raechel Del; Agan, Brian K.; Hale, Braden R.

In: Neurology, Vol. 80, No. 4, 22.01.2013, p. 371-379.

Research output: Contribution to journalArticle

Crum-Cianflone, NF, Moore, DJ, Letendre, S, Roediger, MP, Eberly, L, Weintrob, A, Ganesan, A, Johnson, E, Rosario, RD, Agan, BK & Hale, BR 2013, 'Low prevalence of neurocognitive impairment in early diagnosed and managed HIV-infected persons', Neurology, vol. 80, no. 4, pp. 371-379. https://doi.org/10.1212/WNL.0b013e31827f0776
Crum-Cianflone NF, Moore DJ, Letendre S, Roediger MP, Eberly L, Weintrob A et al. Low prevalence of neurocognitive impairment in early diagnosed and managed HIV-infected persons. Neurology. 2013 Jan 22;80(4):371-379. https://doi.org/10.1212/WNL.0b013e31827f0776
Crum-Cianflone, Nancy F. ; Moore, David J. ; Letendre, Scott ; Roediger, Mollie Poehlman ; Eberly, Lynn ; Weintrob, Amy ; Ganesan, Anuradha ; Johnson, Erica ; Rosario, Raechel Del ; Agan, Brian K. ; Hale, Braden R. / Low prevalence of neurocognitive impairment in early diagnosed and managed HIV-infected persons. In: Neurology. 2013 ; Vol. 80, No. 4. pp. 371-379.
@article{611a5f1c3e2b475fa40837e86e5181a5,
title = "Low prevalence of neurocognitive impairment in early diagnosed and managed HIV-infected persons",
abstract = "Objective: To describe the prevalence of neurocognitive impairment (NCI) among early diagnosed and managed HIV-infected persons (HIV+) compared to HIV-negative controls. Methods: We performed a cross-sectional study among 200 HIV+ and 50 matched HIV-uninfected (HIV-) military beneficiaries. HIV+ patients were categorized as earlier (200 cells/mm3) or later stage patients (n = 100 in each group); both groups were diagnosed early and had access to care. NCI was diagnosed using a comprehensive battery of standardized neuropsychological tests. Results: HIV+ patients had a median age of 36 years, 91{\%} were seroconverters (median window of 1.2 years), had a median duration of HIV of 5 years, had a CD4 nadir of 319, had current CD4 of 546 cells/mm3, and 64{\%} were on highly active antiretroviral therapy (initiated 1.3 years after diagnosis at a median CD4 of 333 cells/mm3). NCI was diagnosed among 38 (19{\%}, 95{\%} confidence interval 14{\%}-25{\%}) HIV+ patients, with a similar prevalence of NCI among earlier and later stage patients (18{\%} vs 20{\%}, p = 0.72). The prevalence of NCI among HIV+ patients was similar to HIV-patients. Conclusions: HIV+ patients diagnosed and managed early during the course of HIV infection had a low prevalence of NCI, comparable to matched HIV-uninfected persons. Early recognition and management of HIV infection may be important in limiting neurocognitive impairment.",
author = "Crum-Cianflone, {Nancy F.} and Moore, {David J.} and Scott Letendre and Roediger, {Mollie Poehlman} and Lynn Eberly and Amy Weintrob and Anuradha Ganesan and Erica Johnson and Rosario, {Raechel Del} and Agan, {Brian K.} and Hale, {Braden R.}",
year = "2013",
month = "1",
day = "22",
doi = "10.1212/WNL.0b013e31827f0776",
language = "English (US)",
volume = "80",
pages = "371--379",
journal = "Neurology",
issn = "0028-3878",
publisher = "Lippincott Williams and Wilkins",
number = "4",

}

TY - JOUR

T1 - Low prevalence of neurocognitive impairment in early diagnosed and managed HIV-infected persons

AU - Crum-Cianflone, Nancy F.

AU - Moore, David J.

AU - Letendre, Scott

AU - Roediger, Mollie Poehlman

AU - Eberly, Lynn

AU - Weintrob, Amy

AU - Ganesan, Anuradha

AU - Johnson, Erica

AU - Rosario, Raechel Del

AU - Agan, Brian K.

AU - Hale, Braden R.

PY - 2013/1/22

Y1 - 2013/1/22

N2 - Objective: To describe the prevalence of neurocognitive impairment (NCI) among early diagnosed and managed HIV-infected persons (HIV+) compared to HIV-negative controls. Methods: We performed a cross-sectional study among 200 HIV+ and 50 matched HIV-uninfected (HIV-) military beneficiaries. HIV+ patients were categorized as earlier (200 cells/mm3) or later stage patients (n = 100 in each group); both groups were diagnosed early and had access to care. NCI was diagnosed using a comprehensive battery of standardized neuropsychological tests. Results: HIV+ patients had a median age of 36 years, 91% were seroconverters (median window of 1.2 years), had a median duration of HIV of 5 years, had a CD4 nadir of 319, had current CD4 of 546 cells/mm3, and 64% were on highly active antiretroviral therapy (initiated 1.3 years after diagnosis at a median CD4 of 333 cells/mm3). NCI was diagnosed among 38 (19%, 95% confidence interval 14%-25%) HIV+ patients, with a similar prevalence of NCI among earlier and later stage patients (18% vs 20%, p = 0.72). The prevalence of NCI among HIV+ patients was similar to HIV-patients. Conclusions: HIV+ patients diagnosed and managed early during the course of HIV infection had a low prevalence of NCI, comparable to matched HIV-uninfected persons. Early recognition and management of HIV infection may be important in limiting neurocognitive impairment.

AB - Objective: To describe the prevalence of neurocognitive impairment (NCI) among early diagnosed and managed HIV-infected persons (HIV+) compared to HIV-negative controls. Methods: We performed a cross-sectional study among 200 HIV+ and 50 matched HIV-uninfected (HIV-) military beneficiaries. HIV+ patients were categorized as earlier (200 cells/mm3) or later stage patients (n = 100 in each group); both groups were diagnosed early and had access to care. NCI was diagnosed using a comprehensive battery of standardized neuropsychological tests. Results: HIV+ patients had a median age of 36 years, 91% were seroconverters (median window of 1.2 years), had a median duration of HIV of 5 years, had a CD4 nadir of 319, had current CD4 of 546 cells/mm3, and 64% were on highly active antiretroviral therapy (initiated 1.3 years after diagnosis at a median CD4 of 333 cells/mm3). NCI was diagnosed among 38 (19%, 95% confidence interval 14%-25%) HIV+ patients, with a similar prevalence of NCI among earlier and later stage patients (18% vs 20%, p = 0.72). The prevalence of NCI among HIV+ patients was similar to HIV-patients. Conclusions: HIV+ patients diagnosed and managed early during the course of HIV infection had a low prevalence of NCI, comparable to matched HIV-uninfected persons. Early recognition and management of HIV infection may be important in limiting neurocognitive impairment.

UR - http://www.scopus.com/inward/record.url?scp=84873669536&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84873669536&partnerID=8YFLogxK

U2 - 10.1212/WNL.0b013e31827f0776

DO - 10.1212/WNL.0b013e31827f0776

M3 - Article

C2 - 23303852

AN - SCOPUS:84873669536

VL - 80

SP - 371

EP - 379

JO - Neurology

JF - Neurology

SN - 0028-3878

IS - 4

ER -